Immunic, Inc.

IMUX · Nasdaq · United States

Share price · IMUX

$7.52-9.38 (-55.50%) 3M

close as of 2026-11-18 · 24h delayed · vol 176K (0.6x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when IMUX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 13 Oct 2026-13.3%
  2. 2 Oct 2026-7.9%
  3. 23 Sep 2026-13.6%
  4. 3 Sep 2026-10.4%
  5. 1 Sep 2026-7.7%
  6. 11 Aug 2026+9.8%
  7. 27 Apr 2026+1034.0%

    Nothing announced by IMUX that day or the session before.

  8. 13 Mar 2026-14.6%
  9. 11 Mar 2026+12.4%
  10. 19 Feb 2026+11.1%

Share of unusual movement by asset

For each asset, the share of IMUX's own-move activity since 3 Sep 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
vidofludimus calcium
events and moves
90%
Other company news (earnings, financing, releases naming no asset)—0%
Sessions with no dated event—100%

Assets

(2 total)
2Total Assets
0Approved
1Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 3
Dihydroorotate dehydrogenase (DHODH)
Multiple Sclerosis
Preclinical / Unstaged
SIRT6Small molecule
Celiac Disease

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
November 2026 (2)
vidofludimus calciumPhase 3Multiple Sclerosis
Est. primary completion 2026-11 · NCT05134441 · CT.gov ↗
What to watch
vidofludimus calciumPhase 3Multiple Sclerosis, Relapsing-Remitting
Est. primary completion 2026-11 · NCT05201638 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

30 April 2025Topline resultvidofludimus calciumCALLIPER Phase 2 (NCT05054140) top-line: modest effect on the exploratory primary brain-volume endpoint; 20% lower risk of 24-week confirmed disability worsening
Immunic, Inc. · Source ↗

Financial reports

Quarterly & interim (17)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$24M$132M$42M-$28M operating cash flowreport ↗
View 16 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$26M$155M$34M-$31M operating cash flowreport ↗
2026-Q1—$26M$187M$33M-$17M operating cash flowreport ↗
2025-Q3—$20M$35M$26M-$20M operating cash flowreport ↗
2025-Q2—$21M$55M$27M-$25M operating cash flowreport ↗
2025-Q1—$22M$14M$25M-$22M operating cash flowreport ↗
2024-Q3—$21M$59M$24M-$21M operating cash flowreport ↗
2024-Q2—$18M$80M$21M-$17M operating cash flowreport ↗
2024-Q1—$19M$97M$30M-$24M operating cash flowreport ↗
2023-Q3—$20M$60M+ $0 short-term inv.$23M-$17M operating cash flowreport ↗
2023-Q2—$21M$77M+ $0 short-term inv.$24M-$20M operating cash flowreport ↗
2023-Q1—$23M$93M+ $4.3M short-term inv.$25M-$20M operating cash flowreport ↗
2022-Q3—$17M$73M$21M-$14M operating cash flowreport ↗
2022-Q2—$17M$88M$22M-$16M operating cash flowreport ↗
2022-Q1—$17M$96M$21M-$21M operating cash flowreport ↗
2021-Q4——$87M+ $0 short-term inv.$21M-$24M operating cash flowreport ↗
2021-Q3—$15M$110M$19M-$18M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$82M$15M$24M-$86M operating cash flowreport ↗
View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$80M$36M$25M-$85M operating cash flowreport ↗
2023-FY—$83M$47M+ $0 short-term inv.$23M-$71M operating cash flowreport ↗
2022-FY—$71M$107M+ $9.6M short-term inv.$30M-$65M operating cash flowreport ↗
2021-FY—$61M$87M+ $0 short-term inv.$23M-$83M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-09-16BVF PARTNERS L P/IL; BIOTECHNOLOGY VALUE FUND L P; BVF I GP LLC; BIOTECHNOLOGY VALUE FUND II LP; BVF II GP LLC; Biotechnology Value Trading Fund OS LP; BVF Partners OS Ltd.; BVF GP HOLDINGS LLC; BVF INC/IL; LAMPERT MARK N · director; director; director; director; director; director; director; director; director; directorAward / grant (derivative)25,370——Form 4
2026-09-16Nagel Robert Thorvald · directorAward / grant (derivative)25,370——Form 4
2026-08-06Ridloff Elena · directorAward / grant (derivative)50,740——Form 4
2026-07-05Congleton Jon · directorAward / grant (derivative)25,370——Form 4
2026-07-05Neermann Joerg · directorAward / grant (derivative)25,370——Form 4
2026-07-05PHILLIPS BARCLAY A · directorAward / grant (derivative)25,370——Form 4
2026-07-05Rudick Richard Alan · directorAward / grant (derivative)25,370——Form 4
2026-07-05Skerjanec Simona · directorAward / grant (derivative)25,370——Form 4